**Oxaydo® references**

Please note:

* Reference #2 is a database and is therefore not included.
* References #4 and #6 are only available in abstract form.

**References**

1. Oxaydo® [package insert]. Wayne (PA): Egalet US Inc.; 2015 Apr.
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Healthcare; Updated periodically [cited 2015 Dec 8]. Available at: <http://www.thomsonhc.com/>.
3. Acura Pharmaceuticals, Inc. Aversion® Technology [webpage on the Internet]. Acura Pharmaceuticals, Inc; 2011 [cited 2015 Dec 15]. Available from: <http://acurapharm.com/research-development/aversion-technology/>.
4. Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, et al. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (OxectaTM) tablets in nondependent recreational opioid users (abstract). J Opioid Manag. 2012;8(5):315-327.

Egalet acquires/licenses two innovative approved pain products. [press release on the Internet]. GlobeNewswire (CA). 2015 Jan 8 [cited 2015 Dec 16]. Available from: <http://globenewswire.com/news-release/2015/01/08/695948/10114621/en/Egalet-Acquires-Licenses-Two-Innovative-Approved-Pain-Products.html>.

Vuilleumier PH, Stamer UM and Landau R. Pharmacogenomic considerations in opioid analgesia. Pharmacogenomics and Personalized Medicine. 2012;5:73-87.